What changed: Pheochromocytoma and paraganglioma (PPGL)
Every dated change on the records linked to Pheochromocytoma and paraganglioma (PPGL), newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Regulatory1Guideline2Milestone7This record1
September 2026 · 1
May 2025 · 1
2025 · 1
2024 · 1
2018 · 1
2014 · 3
- 2014GuidelinePheochromocytoma and paraganglioma (PPGL)Guideline Endocrine Society 2014: All patients
Germline genetic testing and, for carriers, lifelong biochemical and imaging surveillance; cascade testing of relatives.
- 2014GuidelinePheochromocytoma and paraganglioma (PPGL)Guideline Endocrine Society clinical practice guideline 2014; NCCN Neuroendocrine and Adrenal Tumors: Localised, secreting
Alpha-blockade (phenoxybenzamine or doxazosin) for 7 to 14 days, volume expansion, then laparoscopic or open adrenalectomy; cortical-sparing surgery in hereditary bilateral disease.
- 2014MilestoneGermline (hereditary) testingEndocrine Society guideline recommends germline testing for all
A milestone in how this cancer is treated.